Intercept Accords with Apotex, MSN Labs Nix Ocaliva Patent Trial

Intercept Pharmaceuticals Inc. reached settlements with Apotex Inc. and MSN Laboratories Private Ltd., ending a dispute over generic versions of Ocaliva days before their scheduled bench trial on the validity of patents for the rare-liver-disease treatment.

The agreements, approved Feb. 24 by Judge Maryellen Noreika in the US District Court for the District of Delaware, block copies “except as specifically authorized” by the accords.

Last week, Apotex and MSN Labs agreed that their proposed copies infringe four patents for the drug, which is used to treat primary biliary cholangitis, a chronic disease that slowly destroys the liver’s ...